Stock News

Pangu BioPharma (an aTyr Pharma Subsidiary) and The Hong Kong University of Science and Technology Recognized for Pioneering Work Leading to New Investigational Therapeutic for Lung Disease
aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)
aTyr Pharma to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
Atyr Pharma: 3Q Earnings Snapshot

As seen on...